89694-28-0

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-3-SULFAMOYL-BENZOIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new medications, particularly those aimed at treating bacterial infections.
Used in Dye Industry:
As a chemical compound, 4-AMINO-3-SULFAMOYL-BENZOIC ACID is used as a precursor in the production of dyes, highlighting its versatility in different chemical applications.
Used in Resin and Polymer Production:
4-AMINO-3-SULFAMOYL-BENZOIC ACID is utilized as a building block in the creation of water-soluble resins and polymers, which have a wide range of applications in various industries due to their unique properties.
Used in Agricultural Chemicals:
4-AMINO-3-SULFAMOYL-BENZOIC ACID serves as a precursor in the manufacturing of certain agricultural chemicals, playing a crucial role in the development of products that contribute to agricultural advancements.
Used in Medical Research and Development:
4-AMINO-3-SULFAMOYL-BENZOIC ACID is used as a research compound in the field of medicine, where it is explored for its potential in the development of new medications to combat bacterial infections, showcasing its importance in the ongoing pursuit of medical solutions.

InChI:InChI=1/C7H8N2O4S/c8-5-2-1-4(7(10)11)3-6(5)14(9,12)13/h1-3H,8H2,(H,10,11)(H2,9,12,13)

Upstream product

• 855941-97-8 4-acetylamino-toluene-3-sulfonic acid amide 
• 1205-30-7 4-chloro-3-sulphamoylbenzoic acid 
• 71254-63-2 7-methyl-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide 
• 88-44-8 2-Amino-5-methylbenzenesulfonic acid 
• 74-11-3 para-chlorobenzoic acid 
• 2267-40-5 3-chlorosulfonyl-4-fluoro-benzoic acid 
• 106-49-0 p-toluidine 
• 116436-09-0 4-acetylamino-toluene-3-sulfonyl chloride 
• 201224-76-2 3-oxo-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylic acid 1,1-dioxide 

Downstream Products

• 1321626-02-1 N-methyl-N-phenyl-4H-benzo[e][1,2,4]thiadiazine-7-carboxamide-1,1-dioxide 
• 1432503-72-4 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-4H-benzo[e][1,2,4]thiadiazin-4-yl)acetate 
• 1432503-77-9 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-80-4 methyl 2-(4-bromo-2-fluorobenzyl)-4-(2-methoxy-2-oxoethyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylate-1,1-dioxide 
• 1432503-81-5 methyl 2-(2-(4-bromo-2-fluorobenzyl)-1,1-dioxo-7-(piperidine-1-carbonyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-82-6 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(morpholine-4-carbonyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-83-7 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-84-8 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(dimethylcarbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-86-0 methyl 2-(2-(4-bromo-2-fluorobenzyl)-7-(diethylcarbamoyl)-1,1-dioxo-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-87-1 methyl 4-(2-methoxy-2-oxoethyl)-2-(2,4,5-trifluorobenzyl)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-carboxylate-1,1-dioxide 
• 1432503-89-3 methyl 2-(1,1-dioxo-7-(piperidine-1-carbonyl)-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-91-7 methyl 2-(7-(morpholine-4-carbonyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-93-9 methyl 2-(7-(methyl(phenyl)carbamoyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 
• 1432503-94-0 methyl 2-(7-(dimethylcarbamoyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 

Relevant academic research and scientific papers

CYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase

The development and progression of chronic complications in diabetic patients, such as retinopathy, nephropathy, neuropathy, cataracts, and stroke, are related to the activation and/or overexpression of aldose reductase (ALR2), which is a member of the al

Effect on KATP channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides

The present work explored 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides diversely substituted in the 7-position. Those compounds, structurally related to previously described potassium channel openers such as the benzothiadiazine dioxide BPDZ 73, we

1,2,4-benzothiadiazine derivatives, their preparation and use

1,2,4-Benzothiadiazine derivatives represented by formula wherein D, R1, R2, R3, R4, R5, R12, R13, R14, R15 are defined in the description, composition thereof and methods for preparing the compounds are described.The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.